

Talin1 and Rap1 Are Critical for Osteoclast Function

Wei Zou, Takashi Izawa, Tingting Zhu, Jean Chappel, Karel Otero, Susan J. Monkley, David R. Critchley, Brian G. Petrich, Alexei Morozov, Mark H. Ginsberg and Steven L. Teitelbaum

Mol. Cell. Biol. 2013, 33(4):830. DOI: 10.1128/MCB.00790-12. Published Ahead of Print 10 December 2012.

Updated information and services can be found at:
<http://mcb.asm.org/content/33/4/830>

	<i>These include:</i>
REFERENCES	This article cites 38 articles, 14 of which can be accessed free at: http://mcb.asm.org/content/33/4/830#ref-list-1
CONTENT ALERTS	Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

Talin1 and Rap1 Are Critical for Osteoclast Function

Wei Zou,^a Takashi Izawa,^a Tingting Zhu,^a Jean Chappel,^a Karel Otero,^a Susan J. Monkley,^c David R. Critchley,^c Brian G. Petrich,^d Alexei Morozov,^e Mark H. Ginsberg,^d Steven L. Teitelbaum^{a,b}

Department of Pathology and Immunology^a and Department of Medicine, Division of Bone and Mineral Diseases,^b Washington University School of Medicine, St. Louis, Missouri, USA; Department of Biochemistry, University of Leicester, Leicester, United Kingdom^c; Department of Medicine, University of California, San Diego, La Jolla, California, USA^d; Unit on Behavioral Genetics, Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA^e

To determine talin1's role in osteoclasts, we mated *TLN1*^{fl/fl} mice with those expressing cathepsin K-Cre (*CtsK-TLN1*) to delete the gene in mature osteoclasts or with lysozyme M-Cre (*LysM-TLN1*) mice to delete *TLN1* in all osteoclast lineage cells. Absence of *TLN1* impairs macrophage colony-stimulating factor (M-CSF)-stimulated inside-out integrin activation and cytoskeleton organization in mature osteoclasts. Talin1-deficient precursors normally express osteoclast differentiation markers when exposed to M-CSF and receptor activator of nuclear factor κ B (RANK) ligand but attach to substrate and migrate poorly, arresting their development into mature resorptive cells. In keeping with inhibited resorption, *CtsK-TLN1* mice exhibit an \sim 5-fold increase in bone mass. Osteoclast-specific deletion of Rap1 (*CtsK-Rap1*), which promotes talin/ β integrin recognition, yields similar osteopetrotic mice. The fact that the osteopetrosis of *CtsK-TLN1* and *CtsK-Rap1* mice is substantially more severe than that of those lacking α v β 3 is likely due to added failed activation of β 1 integrins. In keeping with osteoclast dysfunction, mice in whom talin is deleted late in the course of osteoclastogenesis are substantially protected from ovariectomy-induced osteoporosis and the periarticular osteolysis attending inflammatory arthritis. Thus, talin1 and Rap1 are critical for resorptive function, and their selective inhibition in mature osteoclasts retards pathological bone loss.

The osteoclast is the principal, if not exclusive, skeletal resorptive cell whose activity is initiated by contact with bone. In all cells, including osteoclasts, integrins recognize substrate, participate in cytoskeletal organization, and transmit matrix-derived signals, events essential to the resorptive process (1, 2).

α v β 3 is the principal integrin mediating the osteoclast's capacity to resorb bone. This heterodimer remodels the cell's cytoskeleton via recruitment of a complex including c-Src, Syk, Dap12, SLP-76, and Vav3. In consequence, the cytoskeleton-organizing GTPase Rac transits from its inactive GDP- to its active GTP-bound form. Absence of any component of this signaling pathway yields a common osteoclast phenotype with a deranged cytoskeleton and inability to spread (3–8). Macrophage colony-stimulating factor (M-CSF), which promotes osteoclastogenesis, also organizes the cytoskeleton of the mature bone resorptive cell by activating a signaling complex strikingly similar to that stimulated by α v β 3 (9, 10).

In osteoclasts, α v β 3 mediates bone matrix recognition by binding ligands containing the RGD motif, but its ability to do so depends upon its configuration. Like integrins in other cells, α v β 3 in the osteoclast is maintained in a default low-affinity state by interactions between the α and β subunits (11, 12). In its inactive conformation, the integrin heterodimer assumes a “bent” configuration in which the α and β intracellular domains interact via a membrane-proximal salt bridge. Upon integrin activation (i.e., increased affinity), the salt bridge is disrupted, the cytoplasmic tails separate, and the extracellular domain “straightens” to achieve a configuration permitting it to effectively bind ligand (13).

Integrins are activated by two basic mechanisms (13). Outside-in activation is achieved by initial ligand binding, which causes secondary conformational modifications, further enhancing the integrin's affinity. Outside-in conformational change can also be induced by chemicals or monoclonal antibodies (MAbs) prior to ligand binding. Inside-out activation, on the other hand,

is an indirect process in which signals derived from an occupied receptor, typically that of a cytokine or growth factor, target the intracellular domain of an integrin. Such targeting of α v β 3 disrupts its salt bridge, separates its tails, and straightens the bent conformation of its external domain. The integrin is now positioned to bind ligand with high affinity and transmit matrix-derived signals, including those that organize the cytoskeleton.

Virtually all studies of integrin function in the osteoclast have focused on outside-in signaling. These experiments typically entail parachuting suspended, preterminally differentiated osteoclastic cells onto an α v β 3 ligand. This approach, however, does not mirror the resorptive process, in which osteoclasts are attached to the bone surface and constantly remodel their cytoskeleton as they move and degrade skeletal tissue. Nor does it mimic the physiological setting, in which cells are exposed to an array of cytokines and growth factors with the potential to alter integrin conformation.

Talin is a 270-kDa cytosolic adaptor protein that links β integrins to the actin cytoskeleton and in so doing regulates multiple biological events such as macrophage participation in innate immunity (14). In all cells studied, the interaction between talin and the β -integrin cytoplasmic domain is a final common and necessary step to inside-out integrin activation (15). The high-affinity heterodimer now avidly binds extracellular ligand, which stimulates the transmission of intracellular signals, including those that

Received 18 October 2012 Returned for modification 2 December 2012

Accepted 5 December 2012

Published ahead of print 10 December 2012

Address correspondence to Steven L. Teitelbaum, teitelbs@wustl.edu.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/MCB.00790-12

organize the cytoskeleton. We find that M-CSF, which activates $\alpha\text{v}\beta 3$ in osteoclasts, promotes the association of integrin with talin via Y747 in the $\beta 3$ tail. Likely reflecting the inhibition of multiple integrins, we also note that conditional deletion of talin or its activator Rap1, in mature osteoclasts, arrests the resorptive function and increases bone mass substantially more than does absence of $\alpha\text{v}\beta 3$. Additionally, osteoclast-specific talin deletion protects against estrogen-deficient osteoporosis and inflammatory osteolysis. Our observation that the pronounced bone-sparing effect of deleting talin or Rap1 occurs only in committed bone resorbing cells gives credence to a therapeutic strategy that avoids targeting early osteoclast precursors such as macrophages. Hence, the Rap1/talin signaling complex is a necessary component of physiological and pathological bone resorption.

MATERIALS AND METHODS

Mice. Generation of *Tln1*^{fl/fl}, $\beta 3$ ^{Y747A}, and *Rap1A*^{fl/fl} *Rap1B*^{fl/fl} mice has been described (16–18). *CtsK*^{cre/+} mice were provided by S. Kato (University of Tokyo, Tokyo, Japan) (19). *LysMCre*-expressing mice were purchased from the Jackson laboratory. To obtain mice with talin1-deficient macrophages (*LysM-TLN*), *Tln1*^{fl/fl} *LysMCre*^{+ /^{WT}} males were bred with *Tln1*^{fl/fl} *LysMCre*^{+ /^{WT}} females. In all experiments, *Tln1*^{fl/fl} *Cre*⁺ or *Rap1A/B*^{fl/fl} *Cre*⁺ mice were compared with *Tln1*^{fl/fl} *Cre*⁻ or *Rap1A/B*^{fl/fl} *Cre*⁻ sex-matched littermates.

Reagents. Recombinant murine M-CSF was obtained from R&D Systems (Minneapolis, MN). Glutathione S-transferase-receptor activator of nuclear factor κB ligand (GST-RANKL) was expressed in our laboratory as described previously (6). The sources of antibodies are as follows: mouse antitalin MAbs and antiactin antibodies were from Sigma (St. Louis, MO); antiphosphotyrosine MAb 4G10 was from Upstate (Charlottesville, VA); MAb 327, directed against the c-Src protein, was a gift of A. Shaw (Department of Pathology, Washington University School of Medicine, St. Louis, MO); rabbit anti-Src p-Y416 antibody and rabbit anti- $\beta 3$ integrin antibody were from Cell Signaling (Beverly, MA). Anti-NFATc1, anti-Rap1A, and anti-Rap1B antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). WOW1 ligand mimetic, which recognizes activated $\alpha\text{v}\beta 3$ integrin, was provided by Sanford Shattil (University of California at San Diego). All other chemicals were obtained from Sigma.

Macrophage isolation and osteoclast culture. Primary bone marrow macrophages (BMMs) were prepared as described previously (6), with slight modification. Marrow was extracted from femora and tibiae of 6- to 8-week-old mice with α -minimal essential medium (α -MEM) and cultured in α -MEM containing 10% inactivated fetal bovine serum (FBS), 100 IU/ml penicillin, and 100 $\mu\text{g}/\text{ml}$ streptomycin (α -10 medium) with 1:10 CMG medium (conditioned medium containing 100 ng/ml mouse M-CSF) (20) on bacterial plastic dishes. Cells were incubated at 37°C in 6% CO_2 for 3 days and then washed with phosphate-buffered saline (PBS) and lifted with 1 \times trypsin/EDTA (Invitrogen, Carlsbad, CA) in PBS. A total of 5 \times 10³ cells were cultured in 200 μl α -MEM containing 10% heat-inactivated FBS with 100 ng/ml GST-RANKL and 30 ng/ml of mouse recombinant M-CSF in 96-well tissue culture plates, some containing sterile bone slices. Cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP) activity after 6 days in culture, using a commercial kit (Sigma 387-A, St. Louis, MO). For preosteoclast generation, 1.5 \times 10⁶ BMMs were plated per 10-cm tissue culture dish and maintained in 30 ng/ml M-CSF and 100 ng/ml GST-RANKL for 3 days.

Actin ring and bone resorptive pit visualization. For actin ring staining, cells were cultured on bovine bone slices in the presence of M-CSF and RANKL for 6 days, after which cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100, rinsed in PBS, and immunostained with AlexaFluor 488-phalloidin (Molecule Probes). To quantitate resorption lacunae, cells were removed from bone slices with mechanical agitation. Bone slices were incubated with peroxidase-conjugated wheat

germ agglutinin (WGA) (Sigma) for 1 h and stained with 3,3'-diaminobenzidine (Sigma).

Plasmids and retroviral transduction. Talin head constructs containing amino acids 1 to 433 were inserted into a pMX retrovirus vector in which the puromycin resistance sequence was replaced with one coding for blasticidin resistance. Generation of the pMX Turbo-Cre construct has been described (21). It was transfected transiently into Plat-E packaging cells using FuGENE 6 transfection reagent (Roche). Virus was collected 48 h after transfection. BMMs were infected with virus for 24 h in the presence of 100 ng/ml M-CSF and 4 $\mu\text{g}/\text{ml}$ Polybrene (Sigma). Cells were selected in the presence of M-CSF and 1 $\mu\text{g}/\text{ml}$ blasticidin (Calbiochem) for 3 days prior to use as osteoclast precursors.

RNA preparation and RT-PCR analyses. Total RNA from cultured cells was isolated using the Total RNA Isolation kit (Sigma). For reverse transcription-PCR (RT-PCR) analysis, cDNAs were synthesized from 1 μg of total RNA using reverse transcriptase and oligo(dT) primers in a volume of 20 μl . The reaction mixture was adjusted to 100 μl with Tris-EDTA (TE) buffer for PCR analysis. PCR was performed with 1 μl of cDNA reaction mixture by using Platinum Pfx polymerase (Invitrogen, Carlsbad, CA) and appropriate primers in a volume of 50 μl . The following primers were used: for *Tln1*, 5'-CAGAGCCCGTAGAAGACCTG and 3'-GGCTGGTGTGGTGGT; for *Tln2*, 5'-TGCAATGTGGTGAA GACCAT and 3'-GTGTCCGACCTGCTTCTAGC; and for *b3*, 5'-TTAC CCGTGGACATCTACTA and 3'-AGTCTTCCATCCAGGGCAATA.

Western blotting and immunoprecipitation. Cultured cells were washed twice with ice-cold PBS and lysed in radioimmunoprecipitation assay (RIPA) buffer containing 20 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β -glycerophosphate, 1 mM Na_3VO_4 , 1 mM NaF, and 1 \times protease inhibitor mixture (Roche). After incubation on ice for 10 min, cell lysates were clarified by centrifugation at 21.1 \times 10³ g for 10 min. Forty micrograms of total lysates was subjected to 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride (PVDF) membranes. Filters were blocked in 0.1% casein in PBS for 1 h and incubated with primary antibodies at 4°C overnight followed by probing with fluorescence-labeled secondary antibodies (Jackson Lab). Proteins were detected with the Odyssey Infrared Imaging system (LI-COR Biosciences).

Rac1 and Rap1 activation assay. Preosteoclasts cultured on plastic dish or bone powder were stimulated with M-CSF and lysed, and Rac or Rap1 activity was determined by an effector domain, GST-fusion pull-down protocol using the EZ-detect Rac1 or Rap1 activation kit (Pierce Biotechnology Inc.).

Medium CTx-1 assay. Macrophages were cultured on bone with 100 ng/ml RANKL and 1/100 volume CMG14-12 mouse M-CSF-producing cell line (20) supernatant for 6 days. The medium (α -10) was changed 1 day before harvesting. Medium CTx-1 concentration was determined using the CrossLaps for Culture enzyme-linked immunosorbent assay (ELISA) kit (Nordic Bioscience Diagnosis A/S).

Phagocytosis assay. Thymocytes isolated from 4-week-old C57BL/6 mice were γ -irradiated (1,400 rads) and cultured for 4 h to induce apoptosis. Thymocytes were 50 to 60% apoptotic as assessed by fluorescein isothiocyanate (FITC)-annexin V (BD Pharmingen) and 7-ADD (Calbiochem) staining (annexin V⁺, 7-ADD⁻). CFSE (5,6-carboxyfluorescein diacetate succinimidyl ester) (5 μM) was used to label thymocytes for 10 min at room temperature. Labeled thymocytes were cocultured with macrophages at a ratio of 5:1 at 37°C. Cells were harvested with PBS-EDTA, stained with CD11b-allophycocyanin (CD11b-APC), and analyzed by flow cytometry. The percentage of phagocytosis was calculated as the fraction of CD11b⁺ cells that were positive in the FL1 channel.

Serum osteocalcin measurements. Blood was collected retro-orbitally under anesthesia immediately prior to sacrifice. Serum osteocalcin levels were measured by ELISA (Biomedical Technologies Inc.). Plasma was obtained using plasma separator tubes with lithium heparin (Becton, Dickinson).

Microcomputed tomography (μ CT). The trabecular volume in the distal femoral metaphysis or proximal tibia was measured using a Scanco μ CT40 scanner (Scanco Medical AG, Bassersdorf, Switzerland). A threshold of 250 was used for evaluation of all scans. Forty to 100 slices were analyzed, starting with the first slice in which condyles and primary spongiosa were no longer visible.

Calcein labeling. We injected calcein (Sigma) intraperitoneally at 7.5 mg/kg of body weight on days 7 and 2 before killing and then sectioned tibiae in methyl-methacrylate, which were analyzed using BioQuant OsteoII (BioQuant Image Analysis Corporation, Nashville, TN).

Serum transfer arthritis and histological analysis. Arthrogenic serum was obtained from K/B \times N mice (6 to 12 weeks old). Serum (100 μ l per mouse) was injected intraperitoneally on days 7 and 2 prior to sacrifice, whereas 100 μ l of PBS was administered to control animals. Five or more mice were used for each group. Paw thickness was measured daily.

Histology and histomorphometry. The tibiae of 2-month-old mice were fixed with 10% neutral buffered formalin, followed by decalcification in 14% EDTA for 10 days, paraffin embedding, and TRAP staining. Osteoclast perimeters were measured and analyzed using BioQuant OsteoII (BioQuant Image Analysis Corporation, Nashville, TN) in a blinded fashion. Pit areas were measured with ImageJ.

Statistics. Statistical significance was determined using Student's *t* test. All experiments were performed at least twice.

RESULTS

M-CSF stimulates inside-out activation of the α β 3 integrin in osteoclasts. The fact that the signaling events by which M-CSF alters the osteoclast cytoskeleton are similar to those mediated by activated α β 3 suggests a collaborative association. Confirming cytokine dependence on the integrin, M-CSF activation of Rac, the currently established most distal component of a canonical osteoclast cytoskeleton organizing complex, requires α β 3 (Fig. 1A). Establishing that the collaboration between α β 3 and M-CSF reflects inside-out stimulation, the cytokine approximately doubles binding of WOW1, an α β 3 ligand mimetic recognizing the activated integrin (Fig. 1B). Furthermore, α β 3 progressively associates with talin under the influence of M-CSF (Fig. 1C), which also promotes talin migration from the podosome belt to cytoskeleton-induced filipodia (Fig. 1D).

β 3^{Y747} regulates talin-mediated cytoskeletal organization in osteoclasts. In other cells, optimal integrin activation requires talin recognition of β 3^{Y747} (17). To determine if the same is true regarding the organization of the osteoclast cytoskeleton, bone marrow macrophages (BMMs) of knock-in mice bearing an alanine mutation of the residue were differentiated into osteoclasts *in vitro*. These cells, while normal in number, develop the same non-spread, cretated appearance extant in osteoclasts lacking the β 3 integrin or its cytoskeleton-organizing effectors (Fig. 2A and B) (3–8). The abnormal appearance of these mutant cells does not represent arrested differentiation (Fig. 2C). Like cultured β 3-deficient osteoclasts, β 3^{Y747A} cells generate actin rings, but their bone-resorptive activity is diminished (Fig. 2D to G).

Immunoblots of β 3 immunoprecipitates document that M-CSF promotes talin association with wild-type (WT) β 3, but not β 3^{Y747A} (Fig. 2H). In contrast to β 3^{Y747A} osteoclasts, those expressing nonphosphorylatable β 3^{Y747F} are essentially normal (22). Like WT, β 3^{Y747F} completely rescues β 3^{-/-} osteoclasts, whereas β 3^{Y747A} is unable to do so (Fig. 2I). Thus, the mechanism by which β 3^{Y747A} disrupts the cytoskeleton does not reflect arrested phosphorylation. Unlike what is seen in β 3^{-/-} mice, no change in bone mass is evident in those bearing the β 3^{Y747A} mutation at 6 months of age (Fig. 2J) (23), but they are protected from postmenopausal




FIG 1 M-CSF activates α β 3 in osteoclasts. (A) Cytokine-starved, bone-residing WT and β 3^{-/-} perfusion osteoclasts were M-CSF treated over time. Total and GTP-bound Rac levels were determined. (B) Perfusion osteoclasts were cytokine starved, lifted, and treated with M-CSF or carrier for 30 min. WOW1 binding was analyzed by fluorescence-activated cell sorting (FACS). Control binding is normalized to 100% (*, *P* < 0.05). (C) Cytokine-starved β 3^{-/-} perfusion osteoclasts transduced with WT human β 3 were treated with M-CSF over time. β 3 immunoprecipitates were immunoblotted for talin, and the blot was densitometrically analyzed. (D) Cytokine-starved osteoclasts generated from WT BMMs were exposed to M-CSF or carrier for 30 min. The cells were stained for F-actin (green) and talin (red). Arrows indicate filipodia induced by the cytokine. Bar, 50 μ m. Data are representative of 3 independent experiments for panels A to C and 2 experiments for panel D. Numbers next to the gels represent molecular weights (in thousands).




FIG 2 $\beta 3^{Y747}$ regulates osteoclast function. (A) WT or $\beta 3^{Y747A}$ (YA) BMMs were cultured in M-CSF and RANKL for 5 days and stained for TRAP activity. Bar, 200 μm . (B) Quantification of the osteoclasts (Ocs) shown in panel A. (C) WT and $\beta 3^{Y747A}$ BMMs were cultured in M-CSF and RANKL. The osteoclast differentiation markers, $\beta 3$ integrin subunit, NFATc1, and c-Src, were immunoblotted with time. Actin served as loading control. (D) WT and $\beta 3^{Y747A}$ BMMs were cultured in M-CSF and RANKL on bone slices for 6 days. Rhodamine-phalloidin-stained actin rings were visualized by fluorescence microscopy. Bar, 100 μm . (E) After 6 days, the cells were removed and resorption pits visualized by peroxidase-labeled wheat germ agglutinin staining. Bar, 100 μm . (F) Quantitation of resorption pits visualized in panel E. (G) Medium collected from cultures shown in panel E was analyzed for CTx content. (H) Cytokine-starved $\beta 3^{-/-}$ prefusion osteoclasts transduced with WT or Y747A human $\beta 3$ were treated with M-CSF or carrier for 30 min. $\beta 3$ immunoprecipitates were probed for talin. $\beta 3$ integrin served as loading control. (I) Osteoclasts generated from $\beta 3^{-/-}$ BMMs transduced with WT, Y747A, or Y747F (YF) human $\beta 3$ or empty vector were stained for TRAP activity (upper panels; bar, 400 μm). Expression of $\beta 3$ constructs (lower panel) with actin as loading control. (J) μCT image of distal femoral metaphysis of 6-month-old WT and $\beta 3^{Y747A}$ knock-in mice. (K) μCT images of distal femur of WT and $\beta 3^{Y747A}$ mice 4 weeks after ovariectomy. (L) μCT determination of BV/TV of WT and $\beta 3^{Y747A}$ mice 4 weeks after ovariectomy. $n = 3$ per group (*, $P < 0.05$; **, $P < 0.01$). Data are representative of at least 3 independent experiments (panels A through F and J through L) or 2 experiments (panels G and H). Numbers next to the gels represent molecular weights (in thousands).




FIG 3 *TLN1* deletion in mature osteoclasts causes osteopetrosis. (A) *TLN1* and *TLN2* mRNA expression in WT BMMs (Mφ) and osteoclasts (OC) assessed by RT-PCR. The β3 integrin subunit serves as a marker of osteoclast differentiation and actin as loading control (left panel). To validate *TLN2* primers, mRNA expression by macrophages (Mφ), osteoclasts, and osteoblasts (OB) was determined by quantitative PCR (right panel). (B) Radiographs of femurs and tibias/fibulas of 8-week-old control (–) and CtsK-*TLN1* (+) mice. (C) μCT images of distal femoral metaphysis (middle and lower panel) and proximal tibia (upper panels) of control (–) and CtsK-*TLN1* (+) mice. (D) μCT determination of BV/TV, trabecular connectivity, and volumetric bone mineral density (BMD) of distal femoral metaphysis of control (–) and CtsK-*TLN1* (+) mice. (E) Whole-body dual-energy X-ray absorptiometry (DEXA) analysis of areal BMD of control (–) and CtsK-*TLN1* (+) mice. (F) TRAP-stained histological sections of proximal tibia of 8-week-old control (–) and CtsK-*TLN1* (+) mice. Bars: 500 μm (upper panel), 50 μm (lower panel). (G) The total number of osteoclasts normalized to bone surface and the percentage of bone surface to which osteoclasts are juxtaposed in panel F were histomorphometrically determined (*, $P < 0.05$; ***, $P < 0.001$). Data are representative of 2 independent experiments in panel A. At least 10 animals were included in each group in panels B to F and 5 animals in panel G.




FIG 4 *TLN1* deletion in mature osteoclasts does not affect bone formation. (A to D) *CtsK-TLN1* (+) and control (-) mice were administered two time-spaced doses of calcein. (A) Fluorescence microscopic images of proximal tibia. Bars: 400 μ m (upper panel), 100 μ m (lower panel). Calculation of bone formation rates (BFR) (B) and mineral apposition rates (MAR) (C). (D) Circulating osteocalcin of *CtsK-TLN1* (+) and control (-) mice. (E and F) $\beta 3^{fl/fl}$ mice (generated by Katherine Weilbaecher, Washington University School of Medicine) were crossed to those expressing *CtsK-Cre*. (E) $\beta 3$ subunit and c-Src immunoblots of lysates of Cre^+ and Cre^- BMMs exposed to M-CSF (M ϕ), or M-CSF + RANKL (OC) for 6 days. Actin served as loading control. (F) μ CT images of 8-week-old Cre^+ and Cre^- progeny. $n = 5$ in each group in panels A to D; $n = 3$ in panel F. Data are representative of at least 2 independent experiments. Numbers next to the gel represent molecular weights (in thousands).

bone loss (Fig. 2K and L) (24). Hence, $\beta 3^{Y747}$ is essential for talin recognition by the integrin in osteoclasts.

Talin1-deficient osteoclasts are dysfunctional *in vivo*. In some cell types, talin2 can compensate for loss of talin1, but only talin1 is expressed by osteoclasts and their precursors (Fig. 3A) (25, 26). Therefore, we crossed mice with a conditional *TLN1* allele to those expressing cathepsin K Cre (*CtsK-Cre*), which is active only in mature osteoclasts (19) (mice and osteoclasts with conditional deletion of *TLN1* by *CtsK-Cre* are here referred to as *CtsK-TLN1*). In keeping with diminished resorptive activity, *CtsK-TLN1* tibias and femurs are more radiodense than control tibias and femurs (Fig. 3B). Similarly, trabecular bone mass and connectivity, determined by μ CT, is substantially increased in *CtsK-TLN1* mice, as are volumetric and whole-body bone mineral density (BMD) (Fig. 3C to E). Histological analysis confirms enhanced trabecular bone volume (BV/TV) in the mutant mice, despite normal numbers of osteoclasts (Fig. 3F and G). In contrast, histomorphometrically measured bone formation rates in Cre^+ and Cre^- mice are indistinguishable, as is the circulating osteo-

blast function marker osteocalcin (Fig. 4A to D). In keeping with the skeletal consequences of talin deletion likely representing targeting of integrins in addition to $\alpha v\beta 3$, *CtsK*-mediated deletion of only the latter does not impact bone mass in 8-week-old mice (Fig. 4E and F).

Rap1-deficient osteoclasts are dysfunctional. Despite the relatively robust *in vivo* phenotype of *CtsK-TLN1* mice, osteoclasts generated *in vitro*, for 5 days, are normal (Fig. 5A). As seen in Fig. 5B, this unexpected phenomenon likely represents undiminished talin1 protein in these cells until 6 days of culture, the limit of their *in vitro* viability. To circumvent this limitation, we attempted, but failed, to delete the gene by transducing *TLN1^{fl/fl}*-bearing BMMs with Cre recombinase-transduced retrovirus (not shown). Based upon our previous experience that the success of *in vitro* Cre-mediated deletion is gene specific (21, 27), we turned to Rap1, a Ras family GTPase, which in conjunction with Rap1 interacting adaptor molecule (RIAM) mediates talin/integrin recognition (28). Like its effect on Rac (Fig. 1A), M-CSF transits Rap1 to its active, GTP-bound form in perfusion osteoclasts (Fig. 5C).




FIG 5 Rap1-deficient osteoclasts are dysfunctional *in vitro*. (A) CtsK-*TLN1* (+) and control (-) BMMs maintained in M-CSF and RANKL for 5 days were stained for TRAP activity. Bar, 400 μ m. (B) CtsK-*TLN1* BMMs were exposed to M-CSF and RANKL for 2 to 6 days or M-CSF (M) for 6 days. Talin1 and Cre expression were determined by immunoblotting. The β 3 integrin subunit serves as a marker of osteoclast differentiation and actin as loading control. (C) Cytokine-starved, WT perfusion osteoclasts were exposed to increasing amounts of M-CSF for 15 min. Lysate containing GTP-Rap1 was measured by pull-down assay. Total Rap1 served as loading control. (D) *Rap1A^{fl/fl} × Rap1B^{fl/fl}* BMMs were transduced with Cre recombinase (+) or vector (-). Lysates were immunoblotted for Rap1A and Rap1B. Actin served as loading control. (E) *Rap1A^{fl/fl} × Rap1B^{fl/fl}* Cre⁺ and Cre⁻ BMMs were exposed to RANKL and M-CSF for 5 days and stained for TRAP activity. Bar, 100 μ m. (F) The cells were removed and resorption pits (dark brown reaction product) visualized by staining with wheat germ agglutinin. Bar, 100 μ m. (G) Medium was analyzed for CTx content. (H) *Rap1A^{fl/fl} × Rap1B^{fl/fl}* Cre⁺ and Cre⁻ BMMs were treated with M-CSF and RANKL for 2 to 5 days or M-CSF (M) alone for 5 days. NFATc1, β 3 integrin, and c-Src were immunoblotted. Actin served as loading control. (I) Cytokine-starved *Rap1A^{fl/fl} × Rap1B^{fl/fl}* Cre⁺ and Cre⁻ perfusion osteoclasts were lifted and maintained in suspension (S) or plated on vitronectin (A) for 30 min. Vav3 immunoprecipitates were immunoblotted for phosphotyrosine (p-Y) and Vav3. (J) Cytokine-starved *Rap1A^{fl/fl} × Rap1B^{fl/fl}* Cre⁺ and Cre⁻ perfusion osteoclasts were exposed to M-CSF or carrier for 30 min. β 3 integrin immunoprecipitates were immunoblotted for talin and β 3 subunit. Data are representative of at least 3 independent experiments in panels A to F and H to J and 2 in panel G. Numbers next to the gels represent molecular weights (in thousands).

In contrast to our attempts to target *TLN1^{fl/fl}*, Cre-mediated deletion of *Rap1A^{fl/fl}/Rap1B^{fl/fl}* *in vitro* was successful (Fig. 5D). This exercise produced osteoclasts exhibiting the characteristic crenated appearance of those lacking integrin-activated, cytoskeleton-organizing molecules and with compromised bone-resorptive capacity (Fig. 5E to G). In keeping with failed integrin activation, Cre⁺ *Rap1* BMMs normally express differentiation markers under osteoclastogenic conditions (Fig. 4H). Furthermore, liganding of α β 3 does not phosphorylate its effector, Vav3 (Fig. 4I), and M-CSF fails to prompt talin/ β 3 association in the gene-deleted, perfusion osteoclasts (Fig. 4J).

Mice with Rap1-deficient osteoclasts are osteopetrotic. To determine the physiological relevance of Rap1 in osteoclasts, we crossed *Rap1A^{fl/fl}/Rap1B^{fl/fl}* mice to those expressing CtsK-Cre, generating animals whose *in vivo* phenotype mirrors those with conditional deletions of talin in that they develop a marked increase in bone mass despite an abundance of osteoclasts (Fig. 6A to E) (mice and osteoclastic cells with conditional deletions of *Rap1A/B* by CtsK-Cre are here referred to as CtsK-*Rap1*). CtsK-induced loss of Rap1A/B is apparent within 3 days of exposing CtsK-*Rap1* BMMs to M-CSF and receptor activator of nuclear factor κ B ligand (RANKL) (Fig. 6F). In keeping with this early deletion, CtsK-*Rap1* osteoclasts so generated have the crenated appearance characteristic of cytoskeletal disarray (Fig. 6G). Thus, disruption of Rap1/

talin activity arrests integrin function in osteoclasts and inhibits their resorptive activity *in vitro* as well as *in vivo*.

Talin-deficient osteoclast lineage cells are dysfunctional. Our previous experiments indicate that talin deletion late in osteoclastogenesis produces osteopetrosis *in vivo* but fails to yield an abnormal phenotype *ex vivo*. Given the success of *in vitro* *Rap1* targeting, however, we reasoned that deleting *TLN1* in early osteoclast lineage cells *in vivo* would obviate this limitation. To this end, we mated *TLN1^{fl/fl}* mice with those expressing Cre driven by the lysozyme M (*LysM*) promoter, expressed in all myeloid lineage cells (osteoclast lineage cells with conditional deletion of *TLN1* by *LysM-Cre* are here referred to as *LysM-TLN1*). Talin1 is reduced by approximately 65% in *LysM-TLN1* cells (Fig. 7A), while expression of kindlin 3 mRNA, whose product binds and activates integrins, is intact (29–31).

Similar to what is seen in CtsK-*TLN1* mice, the number of osteoclasts in *LysM-TLN1* animals is indistinguishable from that of the control (not shown). While the change is not as dramatic as that occurring in the context of CtsK-Cre, trabecular bone volume of *LysM-TLN1* mice is also significantly increased (Fig. 7B). Whereas cultured CtsK-*TLN1* osteoclast lineage cells appear normal, *LysM-TLN1* precursors cluster and largely fail to attach and spread on substrate, features consistent with integrin dys-




FIG 6 Rap1 deletion in mature osteoclasts causes osteopetrosis. (A) X-rays of femurs of *CtsK-Rap1* (+) and control (–) mice demonstrating enhanced radiopacity of the former. (B) μ CT images of femurs of *CtsK-Rap1* and control mice. (C) Quantitative μ CT data of femurs of *CtsK-Rap1* and control mice. (D) TRAP-stained (red reaction product) histological sections of tibias of *CtsK-Rap1* and control mice. Bars: 500 μ m (upper panel), 100 μ m (lower panel). (E) Histomorphometric quantification of trabecular bone volume and osteoclast abundance shown in panel D. (F) *CtsK-Rap1* BMMs were exposed to M-CSF and RANKL for 2 to 6 days or M-CSF (M) for 6 days. Rap1b expression was determined by immunoblotting. Actin served as loading control and c-Src as a marker of differentiation. (G) Control (–) and *CtsK-Rap1* (+) BMMs were cultured with M-CSF and RANKL for 4 days, after which they were stained for TRAP activity. Bars: 400 μ m (upper panels), 100 μ m (lower panel) (**, $P < 0.01$; ***, $P < 0.001$). $n = 4$ in each group (A to E). Data are representative of 3 independent experiments (F and G). Numbers next to the gel represent molecular weights (in thousands).




FIG 7 *TLN1* deletion in osteoclast lineage cells disrupts BMM adhesion. (A) Talin1 protein (left panel) and quantitative PCR (qPCR)-determined talin1 and kindlin3 mRNA (right panel) expression in LysM-*TLN1* (+) and control (-) BMMs. (B) μ CT image and BV/TV of distal femurs of 8-week-old LysM-*TLN1* (+) and control (-) mice (**, $P < 0.01$). (C) Phase-contrast microscopy of LysM-*TLN1* (+) and control (-) BMMs. Bright cells are those that are nonadherent. Bar, 100 μ m. (D) Cytokine-starved WT macrophages were exposed to M-CSF over time. β 1 integrin immunoprecipitates were immunoblotted for talin and β 1 subunit. IgG served as negative control. (E) Serum/

function (Fig. 7C). The impaired attachment of LysM-*TLN1* BMMs does not, however, promote apoptosis (data not shown).

BMMs do not express α v β 3 until they assume the osteoclast phenotype (32). Talin1, however, also activates other integrins. In fact, M-CSF promotes talin association with the β 1 subunit, which participates in osteoclast function, as documented by co-immunoprecipitation and confocal colocalization with exposure to the cytokine (30, 33) (Fig. 7D and E).

LysM-Cre-mediated *TLN1* deletion impairs osteoclast formation. To assess the phenotype of LysM-*TLN1* osteoclasts, we treated Cre⁺ and Cre⁻ BMMs with M-CSF and RANKL. While abundant, characteristic osteoclasts emerged in control cultures, only a few small, adherent, tartrate-resistant acid phosphatase (TRAP)-positive, talin1-deficient polykaryons appeared (Fig. 8A and B). These cells have abnormal cytoskeletons as evidenced by the presence of numerous minute, actin structures and a paucity of rings (Fig. 8C). Attesting that these features represent failed inside-out integrin activation, they are virtually normalized by the outside-in stimulator, MnCl₂ (Fig. 8D). In contrast, expression of the key osteoclast differentiation markers c-Src and NFATc1 is unaltered in RANKL-treated LysM-*TLN1* cells, regardless of their capacity to adhere to substrate (Fig. 8E). Similarly, LysM-Cre-mediated *TLN1* deletion does not affect M-CSF-induced total tyrosine phosphorylation or signaling important for osteoclast differentiation and survival (Fig. 8F). These observations indicate that osteoclast formation requires matrix adhesion by precursors, regardless of the expression of proteins that specifically regulate the cell's differentiation and function. This conclusion is in keeping with the failure of LysM-*TLN1* BMMs to undergo multinucleation when exposed to IL-4 (Fig. 8G).

As the adhesive properties of their precursors are compromised, one would expect mobilization of osteoclasts in response to a resorptive stimulus to be dampened in LysM-*TLN1* mice. To determine if this is so, we supracalvarially injected Cre⁺ and Cre⁻ mice with RANKL or PBS and stained their calvaria for TRAP activity (34). Whereas control RANKL-injected calvaria contain numerous TRAP-rich resorption areas, they are much less abundant in those of LysM-*TLN1* mice (Fig. 9A and B). Furthermore, calvarial mRNAs of the osteoclast markers cathepsin K and TRAP are induced by RANKL in WT but not LysM-*TLN1* animals (Fig. 9C). Thus, RANKL-enhanced osteoclast formation, *in vitro* and *in vivo*, requires progenitor cell talin expression.

α v β 3, in the osteoclast, stimulates a cytoskeleton-organizing complex in which c-Src is a proximal effector (3, 10, 35). To address this issue in the context of LysM-*TLN1*, we generated Cre⁺ and Cre⁻ pre-fusion osteoclasts. They were lifted and either maintained in suspension or plated on α v β 3 ligand, which activates c-Src in control but not talin-deficient cells (Fig. 9D). Tyrosine phosphorylation of specific components of LysM-*TLN1* total cell lysate is also diminished.

To determine the impact of *TLN1* deletion on integrin-directed movement, the lower surfaces of transwell filters were

cytokine-starved osteoclasts, differentially immunostained for β 1 integrin subunit (green) and talin (red) were exposed to carrier or M-CSF for 5 min. Arrows indicate areas of colocalization. Bar, 50 μ m. Data are representative of at least 3 independent experiments in panels A and C through E, and $n = 12$ in the experiment illustrated in panel B. Numbers next to the gels represent molecular weights (in thousands).




FIG 8 *TLN1* deletion in osteoclast lineage cells disrupts osteoclast formation. (A) *LysM-TLN1* (+) and control (-) BMMs treated with M-CSF and RANKL for 5 days were viewed by phase-contrast microscopy to visualize osteoclasts and nonadherent BMMs. Bar, 100 μ m. (B) Following removal of nonadherent cells illustrated in panel A, the cells were stained for TRAP activity. Bar, 400 μ m. (C) Fibrillar actin of bone-residing *LysM-TLN1* (+) and control (-) osteoclasts was visualized by rhodamine-phalloidin staining. Bar, 100 μ m. (D) Bone-residing *LysM-TLN1* osteoclasts were exposed to MnCl₂ (2 mM) or PBS for 8 h. Fibrillar actin was visualized by rhodamine-phalloidin staining. Bar, 100 μ m. (E) BMMs were treated with M-CSF and RANKL (OC) or M-CSF alone (M ϕ) for 4 days. *LysM-TLN1* cells were separated into adherent and nonadherent components, whereas all control cells were adherent. c-Src and NFATc1 were immunoblotted. Actin served as loading control. (F) *LysM-TLN1* (+) and control (-) BMMs were exposed to M-CSF over time. Lysates were immunoblotted for talin and total phosphotyrosine content (upper panel) or total and phosphorylated AKT and extracellular signal-regulated kinase (ERK) (lower panel). Actin served as loading control. (G) *LysM-TLN1* Cre⁺ and Cre⁻ BMMs were cultured in M-CSF with or without interleukin-4 (IL4) (20 ng/ml) for 24 h. The cells were stained with hematoxylin. Bar, 100 μ m. Data are representative of at least 5 independent experiments (A to C) or at least 3 independent experiments (D to G). Numbers next to the gels represent molecular weights (in thousands).

coated with the α v β 3 ligand vitronectin. *LysM-TLN1* and control prefusion osteoclasts were added to transwells in which the lower chamber did or did not contain M-CSF. Neither genotype migrated toward α v β 3 ligand in the absence of M-CSF (Fig. 9E and F). In the presence of the activating cytokine, directed migration of both is increased but that of talin1-deficient cells is less than one-third of that of WT. Reflective of cytoskeletal dysfunction,

the phagocytic capacity of *LysM-TLN1* BMMs is also impaired (Fig. 9G).

The talin head domain partially rescues talin1-deficient osteoclasts. Talin1 consists of a FERM domain-containing head linked to a long, flexible rod (36). Retroviral expression of the talin1 head (tal¹⁻⁴³³) in *LysM-TLN1* BMMs prompts them to adhere to plastic and spread (Fig. 10A). Furthermore, the tyrosine




FIG 9 *TLN1* deletion in osteoclast lineage cells disrupts osteoclast mobilization. (A) RANKL (50 μ g/mouse/day) was administered supracalvarially to *LysM-TLN1* (+) and control (–) mice for 5 days. Calvaria were fixed and stained for TRAP activity. (B) Calvaria of *LysM-TLN1* (+) and control (–) mice treated as described for panel A were subjected to μ CT. (C) Cathepsin K and TRAP mRNA, isolated from the calvaria shown in panels A and B, was quantitated by qPCR. (D) Cytokine-starved *LysM-TLN1* (+) and control (–) preosteoclasts were lifted and maintained in suspension (S) or plated on vitronectin (A) for 30 min. Lysates were immunoblotted for total phosphotyrosine (p-Y) and activated c-Src (p-Src). Actin served as loading control. (E) Preosteoclast migration was assessed using transwells in which the lower membrane surface was coated with vitronectin in the absence or presence of M-CSF as a chemoattractant. The membrane-residing cells were stained with crystal violet. Bar, 100 μ m. (F) Quantification of cells shown in panel E. (G) Engulfment of apoptotic T cells by *LysM-TLN1* (+) and control (–) BMMs (*, $P < 0.05$; **, $P < 0.01$). Data are representative of at least 2 independent experiments. Numbers next to the gel represent molecular weights (in thousands).

phosphorylation of adherent, head domain-transduced preosteoclast lysate is more profound than that of *Cre*⁺ vector control (Fig. 10B). The talin1 head substantially rescues the appearance and number of *LysM-TLN1* TRAP-stained osteoclasts (Fig. 10C) but not their cytoskeletal abnormalities, as manifested by the persistence of numerous atypical, minute actin structures and a paucity of rings (Fig. 10D).

Talin1-deficient osteoclasts protect against pathological bone loss. Reflecting diminished resorption, μ CT and histomorphometric analysis establishes that *CtsK-TLN1* mice are substantially protected from bone loss following estrogen deprivation (Fig. 11A to C). Similarly, the osteoclasts of *CtsK-TLN1* mice with inflammatory arthritis, while abundant, are generally not juxtaposed to bone and exhibit the crenated appearance of those lack-

ing integrin-activated cytoskeleton-organizing molecules, resulting in much less periarticular erosion (Fig. 11D and E). Thus, talin regulates osteoclast function in physiological and pathological circumstances.

DISCUSSION

There is compelling evidence that M-CSF and α v β 3 interdependently remodel the osteoclast cytoskeleton. For example, the cytokine needs α v β 3 to transit the cytoskeleton-organizing GTPase Rac to its GTP-bound state, and integrin-stimulated Rac, induced by adherence to bone, requires M-CSF. Hence, α v β 3 and M-CSF induction of their associated cytoskeleton-organizing signaling complexes are perhaps related by inside-out activation of the integrin. In fact, we previously determined that M-CSF activates a




FIG 10 Talin1 head domain partially rescues LysM-*TLN1* osteoclast formation. (A) Talin1¹⁻⁴³³ (Head) or vector was retrovirally transduced into LysM-*TLN1* BMMs (+). Vector was also transduced into control BMMs (-). Phase-contrast micrograph of transduced BMMs. Bar, 100 μm. (B) Cytokine-starved, transduced prefusion osteoclasts were maintained in suspension (S) or plated on vitronectin (A) for 30 min. Lysates were immunoblotted for phosphorylated tyrosine (p-Y). Actin served as loading control. (C) Transduced BMMs cultured in M-CSF and RANKL for 5 days were stained for TRAP activity. Bar, 400 μm. (D) Bone-residing transduced BMMs cultured in M-CSF and RANKL for 5 days were stained with rhodamine-phalloidin to visualize fibrillar actin. Bar, 100 μm. Data are representative of at least 3 independent experiments. Numbers next to the gel represent molecular weights (in thousands).

hybrid complex of murine α v and human β 3 (11). We presently show that the same obtains, to a similar extent, in naïve WT cells. Having established that M-CSF is capable of activating α β 3 in the bone-resorbing cell, we turned to the causal mechanisms and biological implications.

Talin recognizes the β 3 integrin cytoplasmic domain by first binding a distal motif containing β 3^{Y747}. Alanine knock-in of this residue largely obviates talin1 recognition and prompts failure of osteoclast spreading *in vitro* (17). In contrast to the alanine substitution, β 3^{Y747F} has no effect on osteoclast formation and function (22). In keeping with this observation, β 3^{Y747F} rescues the β 3^{-/-} osteoclast phenotype as effectively as the WT construct. Because Y>F substitution is more conservative than Y>A, the disruptive effect of β 3^{Y747A} on talin1 recognition likely reflects the conformational change of the integrin rather than failed phosphorylation (25).

To more directly determine the role of talin1 in osteoclast formation and function, we targeted the *TLN1*^{fl/fl} gene by CtsK-Cre, generating mice with a 5-fold increase in bone mass. In keeping with integrin dysfunction, CtsK-*TLN1* osteoclasts are abundant but when stressed, such as in the context of inflammatory osteolysis, fail to spread or normally attach to bone.

Because CtsK is expressed late in osteoclastogenesis, Cre recombinase driven by the enzyme's promoter deletes target genes only in cells substantially committed to the osteoclast phenotype. To assess the impact of talin deletion throughout the osteoclastogenic process, we turned to mice expressing LysM-Cre, which is active in all myeloid cells. LysM-*TLN1* BMMs and prefusion osteoclasts fail to attach to substrate, spread, or activate cytoskeletal-

organizing molecules. LysM-*TLN1* prefusion osteoclasts also do not migrate normally to α v β 3 ligand, another manifestation of defective integrin and cytoskeletal function. Failure of LysM-*TLN1* cells to spread on substrate or migrate is not due to inadequate outside-in integrin activation, since the defect is rescued by MnCl₂. Thus, the functional abnormalities of LysM-*TLN1* osteoclast lineage cells likely reflect failed inside-out integrin activation.

Despite the robust *in vivo* skeletal phenotype of CtsK-*TLN1* mice, osteoclasts generated *in vitro* from these animals are normal, reflecting the persistence of talin protein to the limits of cultured osteoclast viability. To circumvent this limitation, we attempted to delete *TLN1*^{fl/fl} *in vitro* with transduced Cre recombinase. While we have used this strategy successfully in other circumstances (21, 27), we find it to be gene specific and were unsuccessful in the context of talin.

Talin contains two principal regions, the head and rod domains, which interact to autoinhibit the protein (13). Rap1 and its binding partner, RIAM, activate talin1 by exposing its head, which then associates with cytoplasmic tails of β integrins to disrupt their inactivating salt bridge and increase ligand affinity. The talin rod interacts with the cytoskeletal proteins, actin and vinculin. Given that Rap1 is essential for talin-mediated integrin activation, in other circumstances, we attempted to delete it *in vitro* by Cre transduction and were successful in generating osteoclasts with disorganized cytoskeletons. With the realization that Rap1 exerts effects other than talin activation, the identical skeletal appearance of mice lacking either gene provides compelling evidence that the normal appearance of osteoclasts derived from CtsK-*TLN1* BMMs reflects failed deletion of the target protein.




FIG 11 Talin1 deficiency in osteoclasts protects against pathological bone loss. μ CT image of distal femur (A) and histological images of tibia (C) of CtsK-*TLN1* (+) and control (-) mice 4 weeks after sham operation or ovariectomy (OVX). Bar, 500 μ m. (B) μ CT-determined percentage of bone loss in CtsK-*TLN1* (+) and control (-) mice 4 weeks following ovariectomy, relative to sham operation. (D) TRAP-stained histological sections of ankles of CtsK-*TLN1* (+) and control (-) mice 7 days following injection of arthrogenic serum. Bars: 100 μ m (top panel), 25 μ m (bottom panel). (E) Percentage of surface (S) exhibiting erosive features and total number of osteoclasts normalized to bone surface, (the percentage of bone surface to which osteoclasts are juxtaposed) (*, $P < 0.05$; **, $P < 0.01$). $n = 7$ in each group for panels A to C, and $n = 4$ in panels D and E. Data are representative of at least 2 independent experiments.

The magnitude of skeletal resorption is reflective of the number of osteoclasts and the capacity of the individual cell to degrade bone. We have shown that the absence of $\alpha\beta3$ or of members of its activated cytoskeleton-organizing complex arrests osteoclast function but not differentiation. In keeping with the essential role of talin in stimulating this complex, RANKL- and M-CSF-treated LysM-*TLN1* BMMs express normal osteoclastogenic markers and activate relevant signaling molecules. On the other hand, mirroring the absence of $\alpha\beta3$ (37), the number of osteoclasts derived from LysM-*TLN1* BMMs *in vitro* is substantially reduced, a likely

consequence of impaired motility and capacity to multinucleate. It is also reflected by impairment of LysM-*TLN1* mice to mobilize osteoclasts in response to RANKL *in vivo*. The fact that two strains of poorly adherent precursors yield low numbers of osteoclasts in culture is consistent with the postulate that despite expression of normal differentiation markers, acquisition of the osteoclast phenotype requires matrix adherence and migration and is therefore impaired in the face of compromised integrin function.

Notwithstanding substantial deficiencies of osteoclast formation and function *in vitro*, the basal bone mass of LysM-*TLN1*




FIG 12 Proposed model of M-CSF-mediated organization of the osteoclast cytoskeleton. In the current study, we find that ligand occupancy of the M-CSF receptor, c-Fms, transmits GDP-bound Rap1 to its active, GTP-bound state. Active Rap1 promotes association of talin with the cytoplasmic domain of $\alpha_v\beta_3$ integrin, leading to induction of its high-affinity conformation. Upon ligand occupancy, the integrin activates a canonical signaling pathway, which we previously demonstrated consists of c-Src, Syk, Dap 12, and Vav3. The last is a relatively osteoclast-specific Rac guanine nucleotide exchange factor. GTP-Rac organizes the cell's cytoskeleton via Arp2/3 (not shown), including actin ring formation, thus permitting it to resorb bone.

mice, albeit significantly increased, is not as abundant as that of CtsK-*TLN1* animals. This difference, while enigmatic, may represent relative efficiencies of *TLN1* deletion. Temporal differences in Cre expression may also contribute to this discrepancy, as we have observed similar inconsistencies in other circumstances involving the same two Cre-expressing mice (8). Regardless of this conundrum, *LysM-TLN1* mice provided us the means of assessing the role of talin's integrin-activating domain in osteoclasts. We find that expression of the talin1 head in *LysM-TLN1* BMMs normalizes their capacity to adhere to matrix and spread. The transduced head also substantially increases the number of osteoclasts recruited by M-CSF and RANKL. However, consistent with the essential role of the talin1 rod in binding to cytoskeletal proteins (25), neither osteoclast abundance nor appearance is completely rescued in *LysM-TLN1* cells expressing the talin head alone. Thus, intact talin is required to functionally link the integrin to the osteoclast cytoskeleton.

The pragmatic aspect of our study relates to the fact that $\alpha_v\beta_3$ is the only integrin that has served as a clinically tested therapeutic target in the context of osteoporosis (38). The bone-sparing effects of a small-molecule $\alpha_v\beta_3$ inhibitor are relatively modest and thus have not been further pursued. Because the osteopetrotic phenotypes of CtsK-*TLN1*, CtsK-*Rap1*, and *kindlin3*^{-/-} mice are more profound than of those of mice lacking the β_3 integrin (23) or β_3 ^{Y747A}, the therapeutic failure of $\alpha_v\beta_3$ inhibition likely reflects compensation by other integrins, such as those of the β_1 family. Hence, targeting common motifs of numerous integrins that recognize essential activating molecules, such as talin, Rap1, or kindlin3, should be a more promising strategy for preventing and treating pathological osteolysis. Furthermore, our data establish that therapeutic targeting needs not be extant throughout osteoclastogenesis, which would impact other myeloid cells such as

inflammatory macrophages. The fact that inhibition of integrin function late in the course of osteoclast development yields healthy mice substantially resistant to inflammatory osteolysis and estrogen-deficient osteoporosis buttresses this argument.

Thus, we propose the following model of M-CSF-mediated organization of the osteoclast cytoskeleton (Fig. 12). Occupancy of c-Fms changes Rap1-GDP to its active, GTP-bound form. Rap1-GTP induces talin to associate with a variety of β subunit cytoplasmic domains, thus transiting the integrins to their active, high-affinity conformation. Upon binding bone matrix-residing ligand, the integrin activates a canonical signaling complex, the most distal established member being Rac, thus organizing the osteoclast's cytoskeleton and enabling the cell to resorb bone.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health grants AR032788, AR046523, AR054618, AR057037, and AR057235 (S.L.T.) and AR027214 (M.H.G.).

The contents are solely our responsibility and do not necessarily represent the official views of the NIH.

We declare that we have no financial conflicts of interest.

REFERENCES

- Hynes RO. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. *Cell* 69:11–25.
- DeMali KA, Wennerberg K, Burridge K. 2003. Integrin signaling to the actin cytoskeleton. *Curr. Opin. Cell Biol.* 15:572–582.
- Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VLJ, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL. 2007. Syk, c-Src, the $\alpha_v\beta_3$ integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. *J. Cell Biol.* 176:877–888.
- Reeve JL, Zou W, Liu Y, Maltzman JS, Ross FP, Teitelbaum SL. 2009. SLP-76 couples Syk to the osteoclast cytoskeleton. *J. Immunol.* 183:1804–1812.
- Zou W, Zhu T, Craft CS, Broekelmann TJ, Mecham RP, Teitelbaum SL. 2010. Cytoskeletal dysfunction dominates in DAP12-deficient osteoclasts. *J. Cell Sci.* 123:2955–2963.
- Faccio R, Zou W, Colaianni G, Teitelbaum SL, Ross FP. 2003. High dose M-CSF partially rescues the Dap12^{-/-} osteoclast phenotype. *J. Cell. Biochem.* 90:871–883.
- Faccio R, Teitelbaum SL, Fujikawa K, Chappel J, Zallone A, Tybulewicz VL, Ross FP, Swat W. 2005. Vav3 regulates osteoclast function and bone mass. *Nat. Med.* 11:284–290.
- Croke M, Ross FP, Korhonen M, Williams DA, Zou W, Teitelbaum SL. 2011. Rac deletion in osteoclasts causes severe osteopetrosis. *J. Cell Sci.* 124:3811–3821.
- Faccio R, Takeshita S, Colaianni G, Chappel JC, Zallone A, Teitelbaum SL, Ross FP. 2007. M-CSF regulates the cytoskeleton via recruitment of a multimeric signaling complex to c-Fms Tyr-559/697/721. *J. Biol. Chem.* 282:18991–18999.
- Zou W, Reeve JL, Liu Y, Teitelbaum SL, Ross FP. 2008. DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. *Mol. Cell* 31:422–431.
- Faccio R, Novack DV, Zallone A, Ross FP, Teitelbaum SL. 2003. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by β_3 integrin. *J. Cell Biol.* 162:499–509.
- Faccio R, Grano M, Colucci S, Villa A, Giannelli G, Quaranta V, Zallone A. 2002. Localization and possible role of two different $\alpha_v\beta_3$ integrin conformations in resting and resorbing osteoclasts. *J. Cell Sci.* 115:2919–2929.
- Shattil SJ, Kim C, Ginsberg MH. 2010. The final steps of integrin activation: the end game. *Nat. Rev. Mol. Cell Biol.* 11:288–300.
- Lim J, Wiedemann A, Tzircotis G, Monkley SJ, Critchley DR, Caron E. 2007. An essential role for talin during alpha(M)beta(2)-mediated phagocytosis. *Mol. Biol. Cell* 18:976–985.
- Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, Ginsberg MH, Calderwood DA. 2003. Talin binding to integrin β tails: a final common step in integrin activation. *Science* 302:103–106.

16. Petrich BG, Marchese P, Ruggeri ZM, Spiess S, Weichert RA, Ye F, Tiedt R, Skoda RC, Monkley SJ, Critchley DR, Ginsberg MH. 2007. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. *J. Exp. Med.* 204:3103–3111.
17. Petrich BG, Fogelstrand P, Partridge AW, Yousefi N, Ablooglu AJ, Shattil SJ, Ginsberg MH. 2007. The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation. *J. Clin. Invest.* 117:2250–2259.
18. Pan BX, Vautier F, Ito W, Bolshakov VY, Morozov A. 2008. Enhanced cortico-amygdala efficacy and suppressed fear in absence of Rap1. *J. Neurosci.* 28:2089–2098.
19. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S. 2007. Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. *Cell* 130:811–823.
20. Takeshita S, Kaji K, Kudo A. 2000. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. *J. Bone Miner. Res.* 15:1477–1488.
21. Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, Long F, Ross FP, Teitelbaum SL. 2008. NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. *J. Biol. Chem.* 283:6509–6518.
22. Feng X, Novack DV, Faccio R, Ory DS, Aya K, Boyer MI, McHugh KP, Ross FP, Teitelbaum SL. 2001. A Glanzmann's mutation in $\beta 3$ integrin specifically impairs osteoclast function. *J. Clin. Invest.* 107:1137–1144.
23. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. 2000. Mice lacking $\beta 3$ integrins are osteosclerotic because of dysfunctional osteoclasts. *J. Clin. Invest.* 105:433–440.
24. Zhao H, Kitaura H, Sands MS, Ross FP, Teitelbaum SL, Novack DV. 2005. Critical role of $\beta 3$ integrin in experimental postmenopausal osteoporosis. *J. Bone Miner. Res.* 20:2116–2123.
25. Critchley DR. 2009. Biochemical and structural properties of the integrin-associated cytoskeletal protein talin. *Annu. Rev. Biophys.* 38:235–254.
26. Zhang X, Jiang G, Cai Y, Monkley SJ, Critchley DR, Sheetz MP. 2008. Talin depletion reveals independence of initial cell spreading from integrin activation and traction. *Nat. Cell Biol.* 10:1062–1068.
27. Ito Y, Teitelbaum SL, Zou W, Zheng Y, Johnson JF, Chappel J, Ross FP, Zhao H. 2010. Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization. *J. Clin. Invest.* 120:1981–1993.
28. Han J, Lim CJ, Watanabe N, Soriani A, Ratnikov B, Calderwood DA, Puzon-McLaughlin W, Lafuente EM, Boussiotis VA, Shattil SJ, Ginsberg MH. 2006. Reconstructing and deconstructing agonist-induced activation of integrin α IIb β 3. *Curr. Biol.* 16:1796–1806.
29. Moser M, Legate KR, Zent R, Fassler R. 2009. The tail of integrins, talin, and kindlins. *Science* 324:895–899.
30. Schmidt S, Nakchbandi I, Ruppert R, Kawelke N, Hess MW, Pfaller K, Jurdic P, Fassler R, Moser M. 2011. Kindlin-3 is required for beta2 integrin-mediated signaling from multiple integrin classes is required for osteoclast-mediated bone resorption. *J. Cell Biol.* 192:883–897.
31. Moser M, Bauer M, Schmid S, Ruppert R, Schmidt S, Sixt M, Wang HV, Sperandio M, Fassler R. 2009. Kindlin-3 is required for beta2 integrin-mediated leukocyte adhesion to endothelial cells. *Nat. Med.* 15:300–305.
32. Inoue M, Namba N, Chappel J, Teitelbaum SL, Ross FP. 1998. Granulocyte macrophage-colony stimulating factor reciprocally regulates α v β -associated integrins on murine osteoclast precursors. *Mol. Endocrinol.* 12:1955–1962.
33. Helfrich MH, Nesbitt SA, Lakkakorpi PT, Barnes MJ, Bodary SC, Shankar G, Mason WT, Mendrick DL, Vaananen HK, Horton MA. 1996. Beta 1 integrins and osteoclast function: involvement in collagen recognition and bone resorption. *Bone* 19:317–328.
34. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, Tamura T, Ozato K, Choi Y, Ivashkiv LB, Takayanagi H, Kamijo R. 2009. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. *Nat. Med.* 15:1066–1071.
35. Horne WC, Sanjay A, Bruzzaniti A, Baron R. 2005. The role (s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. *Immunol. Rev.* 208:106–125.
36. Campbell ID. 2010. The talin FERM domain is not so FERM. *Structure* 18:1222–1223.
37. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL. 2003. c-Fms and the α v β 3 integrin collaborate during osteoclast differentiation. *J. Clin. Invest.* 111:749–758.
38. Murphy MG, Cerchio K, Stoch SA, Gottesdiener K, Wu M, Recker R, for the L-000845704 Study Group. 2005. Effect of L-000845704, an α v β 3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. *J. Clin. Endocrinol. Metab.* 90:2022–2028.